Morten Marott currently serves as the Managing Director of Biotech Investment Banking at H.C. Wainwright & Co., LLC, where he leverages his extensive background in corporate finance and mergers and acquisitions (M&A) to drive growth and innovation within the biotechnology and specialty pharmaceutical sectors. With...
Morten Marott currently serves as the Managing Director of Biotech Investment Banking at H.C. Wainwright & Co., LLC, where he leverages his extensive background in corporate finance and mergers and acquisitions (M&A) to drive growth and innovation within the biotechnology and specialty pharmaceutical sectors. With a portfolio that encompasses approximately 60 companies, Morten is instrumental in originating and executing a diverse array of mandates, including follow-on and secondary equity offerings, convertible note offerings, and strategic mergers and acquisitions. His deep expertise in the industry is further enhanced by his previous roles as a CFO for public and private biotech firms, as well as his experience as an Equity Research Analyst focused on specialty pharmaceuticals.
Morten’s multifaceted skill set not only includes M&A and private equity but also encompasses financial analysis and business strategy, positioning him as a key player in navigating complex financial landscapes. His ability to assess market trends and identify investment opportunities allows him to provide invaluable insights to clients seeking to optimize their capital structures and achieve their strategic objectives. Reporting directly to the Head of Investment Banking and the President of H.C. Wainwright & Co., Morten plays a pivotal role in shaping the firm’s approach to equity financings and debt offerings, ensuring that clients are well-equipped to capitalize on market dynamics. His commitment to fostering long-term relationships and delivering tailored financial solutions underscores his reputation as a trusted advisor in the biotech investment banking arena.
